The Uromigos Episode 63: The First Uromigos Debate—Front-Line Immune Therapy Versus Maintenance Avelumab in Bladder Cancer

Dr. Peter O’Donnell and Prof. Tom Powles debate front-line treatment options in urothelial cancer.

Related Episodes

Episode 189: The Uromigos Paper of the Month—Robotic Versus Open Cystectomy
Episode 187: Cora Sternberg – The Uromigos Legends Series
The Uromigos Episode 169: Paper of the Month—Novel Neoadjuvant Approaches in UC
The Uromigos Episode 162: Debate—Adjuvant Nivolumab for Bladder Cancer
The Uromigos Episode 161: Platinum Ineligibility in Urothelial Cancer
The Uromigos Episode 156: ASCO GU 2022 First-Line Olaparib and Durvalumab in Bladder Cancer
The Uromigos Episode 151: Bladder Cancer ESMO Guidelines Update
The Uromigos Episode 146: Bladder Cancer Christmas Special
The Uromigos Episode 144: Pembrolizumab for Bladder Cancer
The Uromigos Episode 132: Pembro + sEphB4-HAS in Bladder Cancer